MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI revenue by segment, product and geography
In its fiscal year ending 2025-12-31, MARAVAI LIFESCIENCES HOLDINGS, INC. reported revenue across 2 business segments; the largest, Tri Link Segment, was $120M, 64.5% of the filed sum (-39.0% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Tri Link Segment$120M64.5%-39.0% yoy
- Cygnus Segment$66M35.5%+5.0% yoy
Members sum to the consolidated $186M for this period.
- North America$112Mshare n/a-11.6% yoy
- United States$111Mshare n/a-10.3% yoy
- Asia Pacific$41.5Mshare n/a-53.6% yoy
- EMEA$30.9Mshare n/a-26.5% yoy
- Latin And Central America$971Kshare n/a+46.7% yoy
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- Nucleic Acid Production Segment$47.5M72.1%+65.1% yoy
- Biologics Safety Testing Segment$18.4M27.9%+1.4% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.